Clinical Trials Browser

Phase 1/2 × capmatinib × 90 days × Clear all

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms